AVH.AX - Avita Medical Limited

ASX - ASX Delayed price. Currency in AUD
0.05
+0.00 (+4.17%)
At close: 3:29PM AEDT
Stock chart is not supported by your current browser
Previous close0.05
Open0.05
Bid0.05 x 87828500
Ask0.05 x 18726200
Day's range0.05 - 0.05
52-week range0.05 - 0.14
Volume1,462,776
Avg. volume1,727,050
Market cap59.51M
Beta0.67
PE ratio (TTM)N/A
EPS (TTM)-0.02
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.22
  • Business Wirelast month

    Avita Medical A$16.9 Million Capital Raising

    VALENCIA, Calif. & PERTH, Australia & LONDON--(BUSINESSWIRE)-- Avita Medical (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specialising in the treatment of wounds and skin defects, is undertaking a capital raising in aggregate to raise A$16.9 million towards its preparedness for US ReCell commercialisation for burn injuries and to further evaluate new indications. Avita has received commitments from wholesale and institutional investors for a private placement of A$4.5 million at an issue price of A$0.045 per Avita share (Private Placement). Avita also proposes to undertake a non-renounceable rights issue to existing shareholders (Rights Issue) offering one new share for each 2.8 existing shares (as at the record date) at the same issue price as under the Private Placement.

  • Business Wire2 months ago

    Avita Medical Announces Submission of U.S. FDA Premarket Approval (PMA) Application for the ReCell® Device for Treatment of Burn Injuries

    VALENCIA, Calif. & PERTH, Australia & LONDON--(BUSINESSWIRE)-- Avita Medical (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today that it has submitted to the Food & Drug Administration (FDA) a Pre-Market Approval (PMA) application for its ReCell® Autologous Cell Harvesting Device for treatment of burn injuries. Use of the ReCell® Autologous Cell Harvesting Device is intended to reduce the amount of skin harvesting required relative to conventional treatment of burn injuries, which has important benefits from both clinical and health economic perspectives.

  • Business Wire2 months ago

    Avita Medical and BARDA Execute a US$24.3m Contract Option

    VALENCIA, Calif. & PERTH, Australia & LONDON--(BUSINESSWIRE)-- Avita Medical (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced the execution of an expanded contract option valued at approximately US$24.3 million. This newly executed contract option establishes funding for key clinical and health economics research in U.S. pediatric burn care and extends Avita’s Project Bioshield contract through to September 2022. The option execution relates to an original contract between Avita Medical and the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response (ASPR).

  • Business Wire2 months ago

    Research Definitively Confirms Superiority of ReCell® for Treatment of Burn Injuries

    VALENCIA, Calif. & PERTH, Australia & LONDON--(BUSINESSWIRE)-- The ReCell® Autologous Cell Harvesting Device effectively reduces the amount of skin harvesting required relative to conventional treatment ...

  • Business Wire3 months ago

    Avita Medical Names Erin Liberto as Chief Commercial Officer

    VALENCIA, Calif. & PERTH, Australia & LONDON--(BUSINESSWIRE)-- Avita Medical, Ltd. (ASX: AVH ), (OTCQX: AVMXY ), a medical device company developing innovative therapeutic solutions derived from the regenerative ...

  • Business Wire3 months ago

    Avita Medical to Present at Wedbush PacGrow Healthcare Conference

    VALENCIA, Calif. & PERTH, Australia & LONDON--(BUSINESSWIRE)-- Avita Medical, Ltd. (ASX: AVH), (OTCQX: AVMXY), a medical device company developing innovative therapeutic solutions derived from the regenerative ...

  • Business Wire4 months ago

    Avita Medical CEO Issues Shareholder Letter

    It is with great pleasure that I write to you as the new CEO of Avita Medical as we move into an exciting new era of commercialization and clinical trials. Avita’s proprietary technology that generates our “spray-on skin” or RES (Regenerative Epithelial Suspension) delivers to the patient an innovative regenerative medicine solution applicable to a broad array of challenging skin conditions. Additionally, I bring to the company notable experience in product development, regulatory affairs, business development, and general management — all of which I trust will be of material value to Avita’s future success.

  • Business Wire5 months ago

    New Randomized Trial Shows ReCell® Heals Donor Sites Faster

    VALENCIA, Calif. & PERTH, Australia & CAMBRIDGE, England--(BUSINESSWIRE)-- Deploying a suspension of cells generated from a ReCell® medical device onto a skin donor site can speed up healing by 30.7% and deliver a superior final outcome, according to the results of a randomized controlled trial involving 106 patients who received skin grafts, Avita Medical (ASX:AVH.AX - News) (OTCQX:AVMXY - News), said today. Avita, a regenerative medicine company focused on the treatment of wounds and skin defects, said the findings reported in the British Journal of Surgery (BJS) further supported its growing data package around its ReCell® autologous cell harvesting device. This is the 3rd randomized controlled trial announced in recent weeks: last month, the Company presented data from two trials conducted at leading burns centers across the US, including successful results from its pivotal trial needed for PMA approval with the Food and Drug Administration.

  • Business Wire6 months ago

    Dr Michael S. Perry Appointed Avita Medical CEO

    VALENCIA, Calif. & PERTH, Australia & CAMBRIDGE, England--(BUSINESSWIRE)-- The board of pioneering regenerative medicine company Avita Medical Limited (ASX: AVH ; OTCQX: AVMXY ) has appointed Dr Michael ...

  • Business Wire6 months ago

    Avita Medical’s Board Show Confidence in Company by Taking Payment in Shares

    NORTHRIDGE, Calif. & PERTH, Australia & CAMBRIDGE, England--(BUSINESSWIRE)-- The board of pioneering regenerative medicine company Avita Medical Limited (ASX: AVH) (OTCQX: AVMXY), have shown a strong vote of confidence in the company by taking part or all of their Director’s fees in the form of shares. The Board policy of Avita is that individual Directors will invest an amount equivalent to 100% of their annual remuneration over a 3-4 year period. This policy follows from the shareholder approval of the employee share plan in November last year.

  • Business Wire6 months ago

    Avita Medical Announces Positive Results from Pivotal Trial

    OTCQX:AVMXY), a regenerative medicine company focused on the treatment of wounds and skin defects, today said it achieved both co-primary endpoints in its pivotal clinical trial which will soon be submitted for U.S. market approval of its ReCell® device to treat severe burns. The company also released supportive results from a previous burns trial in a dual data release. These data will be submitted to the U.S. Food and Drug Administration as part of an application to support Premarket Approval (PMA) for the ReCell® Autologous Cell Harvesting device.

  • Business Wire6 months ago

    Avita Medical Initiates Legal Proceedings to Cancel Renovacare Patent

    OTCQX:AVMXY), a regenerative medicine company focused on the treatment of wounds and skin defects, has filed an Inter Partes Review (IPR) petition against US Patent No. 9,610,430 (the ‘430 patent) owned by Renovacare Sciences Corp., as Avita holds that all claims in the ‘430 patent are unpatentable and should be cancelled. Avita filed the IPR challenge with the US Patent Trial and Appeal Board (PTAB), which has accepted the petition and will now decide whether the case should come to trial. The IPR process allows a petitioner to challenge the validity of a patent by looking at prior art consisting of patents and printed publications.

  • Business Wire6 months ago

    Initial Pre-Emergency Use Authorization Submission Made to U.S. FDA for Use of ReCell® in a Mass Casualty Scenario

    OTCQX:AVMXY), a regenerative medicine company focused on the treatment of wounds and skin defects, has received notification of the initial FDA review of the Pre-EUA (Emergency Use Authorization) submission to allow the emergency deployment of its ReCell® device for a mass casualty event involving burn injuries. The Biomedical Advanced Research and Development Authority (BARDA) filed the Pre-EUA submission, and the review is conducted at this pre-approval stage because, during exigent circumstances, the time available for the submission and review of an EUA request may be severely limited.

  • Business Wire7 months ago

    Avita Medical CEO Shareholder Letter and Quarterly Report

    VALENCIA, Calif. & PERTH, Australia & LONDON--(BUSINESSWIRE)-- Today, the CEO of Avita Medical Limited (ASX: AVH ) (OTCQX: AVMXY ) issued the following letter to shareholders: Dear Shareholder, At the ...

  • Business Wire7 months ago

    U.S. FDA Approves Increased Compassionate Use Patient Cases and Sites for ReCell® in Life-Threatening Injuries

    VALENCIA, Calif. & PERTH, Australia & LONDON--(BUSINESSWIRE)-- The U.S. Food and Drug Administration has approved a further increase in the number of patients who can be treated in the United States with the ReCell® regenerative medical device under a compassionate use protocol, Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY) said today. The regenerative medicine company, which specializes in the treatment of wounds and skin defects, said the FDA had approved its fourth and largest expansion of its Compassionate Use Investigational Device Exemption (IDE) program for ReCell®, now allowing treatment of up to 68 patients who have insufficient healthy skin available for standard skin grafting treatment of their injury.

  • Business Wire8 months ago

    Avita Announces Receipt of $975K R&D Tax Incentive

    VALENCIA, Calif. & PERTH, Australia & CAMBRIDGE, England--(BUSINESSWIRE)-- Avita Medical Limited (ASX: AVH ) (OTCQX: AVMXY ), a regenerative medicine company focused on the treatment of wounds and skin ...

  • Business Wire9 months ago

    Avita Medical Announces Last Patient Visit in U.S. Pivotal Trial

    OTCQX:AVMXY), a regenerative medicine company focused on the treatment of wounds and skin defects, has collected long-term follow-up data from the final patient enrolled in its pivotal FDA trial of the ReCell® Autologous Cell Harvesting Device for the treatment of burns, and achieved a key milestone in its U.S. regulatory pathway, the Company said today. The Company now has the necessary clinical data to conduct the analyses needed for a Premarket Approval (PMA) application.

  • Business Wire9 months ago

    Avita Medical Named to 2017 OTCQX Best 50

    VALENCIA, Calif. & PERTH, Australia & CAMBRIDGE, England--(BUSINESSWIRE)-- Avita Medical Limited (ASX: AVH ) (OTCQX: AVMXY ), a regenerative medicine company focused on the treatment of wounds and skin ...

  • Business Wire10 months ago

    Avita Medical CEO Shareholder Letter and Quarterly Report

    VALENCIA, Calif. & PERTH, Australia & LONDON--(BUSINESSWIRE)-- Avita Medical (OTCQX: AVMXY) (ASX: AVH) today issued the following CEO Shareholder Letter and Quarterly Report: Dear Shareholder, As we conclude ...

  • Business Wire10 months ago

    Avita Medical to Participate in the 3rd Annual Biotech and Money / Medtech and Money London 2017 Conference

    NORTHRIDGE, Calif. & PERTH, Western Australia & LONDON--(BUSINESSWIRE)-- Avita Medical Ltd (ASX: AVH ) (OTCQX: AVMXY ), a regenerative medicine company specializing in new treatments for wounds and skin ...